Bluefield Project to Cure Frontotemporal Dementia

About Bluefield Project to Cure Frontotemporal Dementia

The Bluefield Project to Cure Frontotemporal Dementia centers its grantmaking on translating progranulin (GRN)-related frontotemporal dementia research into drug development. Its stated mission is to move findings from a research consortium into therapies for frontotemporal dementia, with a specific focus on FTD caused by GRN mutations. That mission shows up in repeated research awards to major academic medical centers, including a 2025 grant of $2,409,271 to the University of California, San Francisco and a 2024 grant of $2,394,193 to the same institution. The foundation’s pattern suggests long-running support for the same scientific agenda rather than one-off programmatic interest. Harvard University appears among its larger recipients as well, with grants of $591,391 in 2023 and 2024, alongside a $272,513 award in 2025 to President and Fellows of Harvard College. Memorial Sloan Kettering Cancer Center, Mayo Clinic Rochester, and Emory University also appear in the recent grants list, all marked for research. The funder gives nationally and works through invited research collaborations tied to therapeutic development, biomarker work, and clinical research in FTD.

What Bluefield Project to Cure Frontotemporal Dementia Funds

A major theme in the Bluefield Project’s giving is translational research for progranulin-linked FTD. The Bluefield Research Consortium funds discovery, translational, and clinical research through invitation-only proposals, bringing discovery scientists together with clinical neurologists to speed therapies from bench to clinic. Biomarkers are another visible priority. The foundation’s topic taxonomy includes neurofilament light chain and imaging, which fits its broader clinical-endpoint work in FTD research. Therapeutic platform development also appears in the funder’s focus areas, including gene therapy and gene editing approaches and antisense oligonucleotide therapeutics. The foundation also names lysosomal function, autophagy, TMEM106B, and neuroinflammation among its focus areas. In the recent grants list, the University of Alabama received $180,000 in 2024 for research, and Emory University received $165,000 in both 2023 and 2024 for research, showing sustained support for FTD-focused scientific work.

How Bluefield Project to Cure Frontotemporal Dementia Gives